Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
Screening for SMA in Newborns Alleviates Functional Burden, Associated Comorbidities
January 17th 2023A study found that screening for spinal muscular atrophy (SMA) in newborns paired with early access to disease-modifying therapies was effective in alleviating the burden and comorbidities of the disease.
Read More
The reality of a sickle cell disease cure brings fear, optimism, and questions to patients’ lives; veterans who are in suicidal crisis can receive free emergency care at any Department of Veterans Affairs or private facility; Pfizer to increase access to progressive treatments through sale of drugs at non-profit prices to poor countries.
Read More
No difference in treatment efficacy was observed between intranasal mometasone furoate and saline for the management of sleep-disordered breathing (SDB) symptoms in children, with findings indicating that almost one-half of children with SDB could be initially managed in the primary care setting.
Read More
Paxlovid May Reduce Already Low Risk of COVID-19 Hospitalization, Death Among Vaccinated Patients
January 17th 2023Patients who received nirmatrelvir plus ritonavir (Paxlovid) had lower risk of both hospitalization within 14 days and death within 28 days compared with patients who did not receive the treatment.
Read More
Adherence to Postop Treatment May Indicate Early Recurrence of CRSwNP
January 17th 2023The utility of and adherence to follow-up exams for potential recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) was investigated among 60 patients who had undergone functional endoscopic sinus surgery.
Read More
4-Dose COVID-19 Vaccine Less Effective Beyond 90 Days
January 16th 2023A new study has found that vaccine effectiveness against infection after 4 doses of the COVID-19 vaccine disappeared after 90 days for Omicron variants BA.2, BA.2.12.1, BA.4, and BA.5, although it remained effective against hospitalizations.
Read More
Dr Michael Portman Explains How Cardiac Disease Differs Between Pediatric, Adult Patients
January 16th 2023During an interview at the 2022 American Heart Association Scientific Sessions in Chicago, Michael A. Portman, MD, FAHA, Seattle Children's Hospital addressed how cardiac disease presents in pediatric vs adult patients.
Watch